Double Bond Pharmaceutical International AB (XSAT:DBP B) Interest Coverage: No Debt (1) (As of Mar. 2026) — 100% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:DBP B Double Bond Pharmaceutical International AB XSAT:DBP B
30 GF Score
Price kr0.14
GF Value kr0.06
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Double Bond Pharmaceutical International AB Interest Coverage?

Double Bond Pharmaceutical International AB XSAT:DBP B +2.26% 30 Interest Coverage is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates XSAT:DBP B with a GF Score™ of 30/100 and a GF Value™ of kr0.06 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 376 Biotechnology companies, Double Bond Pharmaceutical International AB ranks worse than 265957.18% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Double Bond Pharmaceutical International AB's Operating Income for the three months ended in Mar. 2026 was kr-0.27 Mil. Double Bond Pharmaceutical International AB's Interest Expense for the three months ended in Mar. 2026 was kr0.00 Mil. Double Bond Pharmaceutical International AB has no debt. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Double Bond Pharmaceutical International AB's Interest Coverage or its related term are showing as below:


XSAT:DBP B's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 104.025
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Double Bond Pharmaceutical International AB  (XSAT:DBP B) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Double Bond Pharmaceutical International AB Interest Coverage Related Terms

Double Bond Pharmaceutical International AB Interest Coverage Historical Data

* Premium members only.

The historical data trend for Double Bond Pharmaceutical International AB's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Double Bond Pharmaceutical International AB Interest Coverage Chart

Double Bond Pharmaceutical International AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 No Debt 0.00 0.00 0.00

Double Bond Pharmaceutical International AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 No Debt No Debt

XSAT:DBP B vs VRTX, REGN, ALNY: Interest Coverage Comparison

For the Biotechnology subindustry, Double Bond Pharmaceutical International AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Double Bond Pharmaceutical International AB Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Double Bond Pharmaceutical International AB's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Double Bond Pharmaceutical International AB's Interest Coverage falls into.


XSAT:DBP B
30GF Score
Double Bond Pharmaceutical International AB XSAT:DBP B
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Double Bond Pharmaceutical International AB Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Double Bond Pharmaceutical International AB's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Double Bond Pharmaceutical International AB's Interest Expense was kr-0.15 Mil. Its Operating Income was kr-1.69 Mil. And its Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.

Double Bond Pharmaceutical International AB did not have earnings to cover the interest expense.

Double Bond Pharmaceutical International AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, Double Bond Pharmaceutical International AB's Interest Expense was kr0.00 Mil. Its Operating Income was kr-0.27 Mil. And its Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.

Double Bond Pharmaceutical International AB had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Double Bond Pharmaceutical International AB (XSAT:DBP B) has a Interest Coverage of No Debt (1) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Double Bond Pharmaceutical International AB and its competitors. This is 100% below median its historical median of 10,000.00. According to the industry distribution chart, Double Bond Pharmaceutical International AB ranks #999999 out of 376 companies in the Biotechnology industry.
Is Double Bond Pharmaceutical International AB's Interest Coverage too high?
Double Bond Pharmaceutical International AB's current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Based on the distribution chart, Double Bond Pharmaceutical International AB ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Double Bond Pharmaceutical International AB has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Double Bond Pharmaceutical International AB's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Double Bond Pharmaceutical International AB ranks #999999 out of 376 companies for Interest Coverage. This places Double Bond Pharmaceutical International AB in the lower half of its industry. The industry median Interest Coverage is 104.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Double Bond Pharmaceutical International AB and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Double Bond Pharmaceutical International AB's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Double Bond Pharmaceutical International AB stock overvalued right now?
Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB (XSAT:DBP B) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.06, compared to a current price of kr0.14 — trading 125.8% above its estimated fair value. The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Double Bond Pharmaceutical International AB's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Double Bond Pharmaceutical International AB (XSAT:DBP B), the current Interest Coverage is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Double Bond Pharmaceutical International AB (XSAT:DBP B) Overvalued in 2026?

Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB stock appears to be overvalued. The current stock price of kr0.14 is trading 125.8% above its estimated GF Value™ of kr0.06. GuruFocus considers Double Bond Pharmaceutical International AB to be Significantly Overvalued.

Key valuation signals for XSAT:DBP B:

  • Interest Coverage: No Debt (1) (100% below median its 10-year median of 10,000.00)
  • GF Value™: kr0.06 vs. price of kr0.14 (125.8% above fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the XSAT:DBP B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Double Bond Pharmaceutical International AB Business Description

Address Virdings Alle 32B, Uppsala, SWE, 75450
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.
30GF Score

Get the complete analysis for XSAT:DBP B

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.14
Price
kr0.06
GF Value